AZD1480An inhibitor of JAK2

AZD1480 (CAS 935666-88-9)

AZD1480 | CAS 935666-88-9 is rated 5.0 out of 5 by 2.
  • y_2019, m_10, d_18, h_11
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_2
  • loc_en_US, sid_364735, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 116ms
  • REVIEWS, PRODUCT
5
2
4
0
3
0
2
0
1
0
Synonym: (S)-5-chloro-N2-(1-(5-fluoropyrimidin-2-yl)ethyl)-N4-(5-methyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine
Application: An inhibitor of JAK2
CAS Number: 935666-88-9
Purity: ≥98%
Molecular Weight: 348.77
Molecular Formula: C14H14ClFN8
* Refer to Certificate of Analysis for lot specific data (including water content).
Submit a review for this product and receive 15 CruzCredits

AZD1480 is a novel ATP-competitive inhibitor of JAK2 (IC50 = 0.26 nM).

Physical State :
Solid
Solubility :
Soluble in DMSO (70 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (<1 mg/ml at 25 °C).
Storage :
Store at -20° C
Melting Point :
213.39° C (Predicted)
Boiling Point :
~575.2° C at 760 mmHg (Predicted)
Density :
~1.5 g/cm3 (Predicted)
Refractive Index :
n20D 1.70 (Predicted)
IC50 :
JAK2: IC50 = 0.26 nM; Trk A: IC50 = 3 nM (human); Stat3: IC50 = 23 nM (human); Stat5a: IC50 = 25 nM (human); JAK3: IC50 = 1.36 µM (human)
pK Values :
pKa: 13.73 (Predicted), pKb: 4.37 (Predicted)
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
PubChem CID :
16659841
MDL Number :
MFCD16038904
SMILES :
CC1=CC(=NN1)NC2=NC(=NC=C2Cl)N[C@@H](C)C3=NC=C(C=N3)F

Download SDS (MSDS)

Certificate of Analysis

Adobe Acrobat Reader is required to reliably view,
print and comment on PDF documents

AZD1480  Product Citations

See how others have used AZD1480. Click on the entry to view the PubMed entry .

Citations 1 to 2 of 2 total

PMID: # 30981183  Hwang, ST.|Kim, C.|Lee, JH.|Chinnathambi, A.|Alharbi, SA.|Shair, OHM.|Sethi, G.|Ahn, KS.| et al. 2019. Phytomedicine. 59: 152907.

PMID: # 27199222  Thorn, M. et al. 2016. Cancer gene therapy. 188-198.

Citations 1 to 2 of 2 total
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 58ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of 5 by from It worked well in our experiments It worked well in our experiments, no complaints.
Date published: 2015-06-05
Rated 5 out of 5 by from Liu X; et al Liu X; et al. (PubMed ID: 25954974) determined that AZD1480, an AK2 inhibitor, blocked the effect of COX-2/PGE2 on expression of MMP-2/-9. -SCBT Publication Review
Date published: 2015-06-05
  • y_2019, m_10, d_18, h_11
  • bvseo_bulk, prod_bvrr, vn_bulk_2.0.13
  • cp_1, bvpage1
  • co_hasreviews, tv_0, tr_2
  • loc_en_US, sid_364735, prod, sort_[SortEntry(order=SUBMISSION_TIME, direction=DESCENDING)]
  • clientName_scbt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 32ms
  • REVIEWS, PRODUCT

Santa Cruz Biotechnology, Inc. is a world leader in the development of products for the biomedical research market. Call us Toll Free at 1-800-457-3801.
Copyright © 2007-2019 Santa Cruz Biotechnology, Inc. All Rights Reserved. "Santa Cruz Biotechnology", and the Santa Cruz Biotechnology, Inc. logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", the San Juan Ranch logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", and "EZ Touch" are registered trademarks of Santa Cruz Biotechnology, Inc.
All trademarks are the property of their respective owners.